To understand Awakn Life Sciences you first have to understand that Psychedelics are going to go through a parabolic, paradigm shifting growth cycle in the next 5 years because of their ability to treat anxiety, depression and addiction.  

$AWKN is a biotechnology company focused on addiction that provides investors with the best of both worlds.  

1. Development: Research & developing the next generation of psychedelic drugs, therapies, and enabling technologies to better treat Addiction.
2. Delivery: Awakn delivers evidence backed psychedelic therapies through its own clinics in the UK and Europe. Global expansion will come from licensing partnerships. 

PARADIGM SHIFTING TRIAL RESULTS

More than just lip service, $AWKN announced what can only be described as mind blowing (pardon the pun) results from Phase 2 of its clinical trial of "Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial" .  How great were these results?

• Mortality reduced to 1/80 patients from 1/8 - a factor of 10!
• Abstinence increased from 2% to 86%
• No serious adverse events

The results were so incredible that $AWKN stated:

"The data we've collected from this study paves the way for a paradigm shift in how Alcohol Use Disorder is treated."

Sit back, relax and watch this powerful interview with CEO Anthony Tennyson.